Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 4 beta 1

Integrin alpha 4 beta 1

Brief Information

Name:Integrin alpha-4/beta-1
Target Synonym:Integrin alpha4beta1
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IT1-H82W1-SPR
 Integrin alpha 4 beta 1 SPR

Human VCAM-1, His Tag (Cat. No. VC1-H5224) immobilized on CM5 Chip can bind Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) with an affinity constant of 253 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

IT1-H52W1-SPR
 Integrin alpha 4 beta 1 SPR

Human VCAM-1, His Tag (Cat. No. VC1-H5224) immobilized on CM5 Chip can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with an affinity constant of 51.3 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

Integrin alpha 4 beta 1,ITGA4&ITGB1,ITGA4&B1

Background

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren Japan Multiple Sclerosis Biogen Inc 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RBx-7796 RBx-7796 Clinical Sun Pharmaceutical Industries Ltd Rhinitis, Allergic; Asthma Details
ATL-1102 ATL-1102; TV-1102; ATL/TV-1102; ISIS-107248 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis; Muscular Dystrophy, Duchenne Details
7HP-349 7HP-349; 7-HP-349 Details
Firategrast T-0047; SB-683699 Mitsubishi Tanabe Pharma Details
Natalizumab biosimilar (Polpharma Biologics) PB-006 Phase 3 Clinical Polpharma Biologics Sa Multiple Sclerosis, Relapsing-Remitting Details
LLP2A alendronate Phase 1 Clinical University Of California Osteonecrosis; Bone Diseases, Metabolic; Osteoporosis; Bone Diseases Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message